163 related articles for article (PubMed ID: 27146673)
1. Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.
Flinders C; Lam L; Rubbi L; Ferrari R; Fitz-Gibbon S; Chen PY; Thompson M; Christofk H; B Agus D; Ruderman D; Mallick P; Pellegrini M
Genome Med; 2016 May; 8(1):54. PubMed ID: 27146673
[TBL] [Abstract][Full Text] [Related]
2. Morphine leads to global genome changes in H3K27me3 levels via a Polycomb Repressive Complex 2 (PRC2) self-regulatory mechanism in mESCs.
Muñoa-Hoyos I; Halsall JA; Araolaza M; Ward C; Garcia I; Urizar-Arenaza I; Gianzo M; Garcia P; Turner B; Subirán N
Clin Epigenetics; 2020 Nov; 12(1):170. PubMed ID: 33168052
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells.
Bouzelfen A; Kora H; Alcantara M; Bertrand P; Latouche JB; Jardin F
Leuk Res; 2017 Sep; 60():53-57. PubMed ID: 28651105
[TBL] [Abstract][Full Text] [Related]
4. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
5. Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes.
Reddington JP; Perricone SM; Nestor CE; Reichmann J; Youngson NA; Suzuki M; Reinhardt D; Dunican DS; Prendergast JG; Mjoseng H; Ramsahoye BH; Whitelaw E; Greally JM; Adams IR; Bickmore WA; Meehan RR
Genome Biol; 2013 Mar; 14(3):R25. PubMed ID: 23531360
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract][Full Text] [Related]
7. Integrative Proteomic Profiling Reveals PRC2-Dependent Epigenetic Crosstalk Maintains Ground-State Pluripotency.
van Mierlo G; Dirks RAM; De Clerck L; Brinkman AB; Huth M; Kloet SL; Saksouk N; Kroeze LI; Willems S; Farlik M; Bock C; Jansen JH; Deforce D; Vermeulen M; Déjardin J; Dhaenens M; Marks H
Cell Stem Cell; 2019 Jan; 24(1):123-137.e8. PubMed ID: 30472157
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic alterations of the keratin 13 gene in oral squamous cell carcinoma.
Naganuma K; Hatta M; Ikebe T; Yamazaki J
BMC Cancer; 2014 Dec; 14():988. PubMed ID: 25527207
[TBL] [Abstract][Full Text] [Related]
9. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
[TBL] [Abstract][Full Text] [Related]
10. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
[TBL] [Abstract][Full Text] [Related]
11. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
12. Cryosectioning the intestinal crypt-villus axis: an ex vivo method to study the dynamics of epigenetic modifications from stem cells to differentiated cells.
Vincent A; Kazmierczak C; Duchêne B; Jonckheere N; Leteurtre E; Van Seuningen I
Stem Cell Res; 2015 Jan; 14(1):105-13. PubMed ID: 25590428
[TBL] [Abstract][Full Text] [Related]
13. Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques.
Wierda RJ; Rietveld IM; van Eggermond MC; Belien JA; van Zwet EW; Lindeman JH; van den Elsen PJ
Life Sci; 2015 May; 129():3-9. PubMed ID: 25445221
[TBL] [Abstract][Full Text] [Related]
14. ABF-1 is frequently silenced by promoter methylation in follicular lymphoma, diffuse large B-cell lymphoma and Burkitt's lymphoma.
Ushmorov A; Leithäuser F; Ritz O; Barth TF; Möller P; Wirth T
Leukemia; 2008 Oct; 22(10):1942-4. PubMed ID: 18368067
[No Abstract] [Full Text] [Related]
15. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
[TBL] [Abstract][Full Text] [Related]
16. Chromatin states of developmentally-regulated genes revealed by DNA and histone methylation patterns in zebrafish embryos.
Lindeman LC; Winata CL; Aanes H; Mathavan S; Alestrom P; Collas P
Int J Dev Biol; 2010; 54(5):803-13. PubMed ID: 20336603
[TBL] [Abstract][Full Text] [Related]
17. Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer.
Tan J; Yang X; Jiang X; Zhou J; Li Z; Lee PL; Li B; Robson P; Yu Q
Cell Death Dis; 2014 Jul; 5(7):e1324. PubMed ID: 25032847
[TBL] [Abstract][Full Text] [Related]
18. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation associated with polycomb repression in retinoic acid receptor β silencing.
Moison C; Senamaud-Beaufort C; Fourrière L; Champion C; Ceccaldi A; Lacomme S; Daunay A; Tost J; Arimondo PB; Guieysse-Peugeot AL
FASEB J; 2013 Apr; 27(4):1468-78. PubMed ID: 23299856
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
